# Actieve studies

| Title | Phase | Tumortype | Line of Therapy | Study Information | Register |
|---|---|---|---|---|---|
| **SABR MESCC**<br>Separation surgery followed by Stereotactic Ablative Body Radiotherapy versus Stereotactic Ablative Body Radiotherapy alone for spinal metastases invading the spinal canal: a randomised, non-inferiority trial | II | All types, patients with spinal M+ | Radiotherapy/Surgery | Multicentre, randomized prospective study to compare stereotactic radiotherapy to separation surgery followed by postoperative SABR in ambulatory patients with malignant epidural spinal cord compression (MESCC). Primary endpoint is ambulatory state at 3 months | PI:<br>Charlotte Billiet, Iridium Netwerk<br>Contact: charlotte.billiet@gza.be |
| **PRIMALUNG**<br>PRophylactic cerebral Irradiation or active brain MAgnetic resonance imaging surveillance in small-cell Lung cancer patients (PRIMALung study). | III | All SCLC (limited and extensive) | Radiotherapy | Academic-led, open-label, multicentre, randomized phase III trial to investigate if overall survival (OS) with brain MRI surveillance alone is non-inferior to brain MRI surveillance combined with prophylactic cranial irradiation (PCI) for the treatment of small cell lung cancer (SCLC) Primary endpoint is OS. | NCT04790253<br>EORTC Lung Cancer Group<br>PI:<br>Prof Corinne Faivre-Finn<br>Local PI:<br>Charlotte Billiet, Iridium Netwerk<br>Contact: charlotte.billiet@gza.be |
| **HiPeRMESO**<br>High-dose Pleural Radiotherapy in Lung-Sparing Multimodality Therapy for Malignant Pleural Mesothelioma | Feasibility | MPM all types (except sarcomatoid | Radiotherapy | Feasibility study for a lung-sparing multimodality therapy in patients with malignant pleural mesothelioma treated with chemotherapy, pleurectomy/decortication and postoperative pleural radiotherapy | PI:<br>Charlotte Billiet, Iridium Netwerk<br>Contact: charlotte.billiet@gza.be |
| **ImmunoSABR**<br>Stereotactic ablative body radiotherapy (SABR) combined with Immunotherapy (L19-IL2) in stage IV NSCLC patients; a multicentre, 1andomized | II | Patients with stage IV NSCLC (max 10 M+) | Immunocytokine L19-IL2 (+/-APD(L)1 treatment if SOC) +/- Radiotherapy (SBRT) | To test the hypothesis that the combination of SABR and L19-IL2 increases the progression-free survival at 1.5 years in patients with limited metastatic NSCLC. Patients will be divided according to their metastatic load (Oligo: up to 5 or Poly: 6 to 10 metastases). Patients will be | NCT03705403<br>PI:<br>Prof Philippe Lambin, Maastricht<br>Local PI:<br>Charlotte Billiet, Iridium Netwerk<br>Contact: charlotte.billiet@gza.be |

## Actieve studies

| | | | | | |
|---|---|---|---|---|---|
| controlled open-label phase II trial | | | | randomized by minimization to the experimental (E-arm) or the control arm. E-arm Oligometastatic patients will receive SABR to a maximum of 5 lesions followed by L19-IL2 therapy; the Poly-metastatic patients will receive radiotherapy to at least one (symptomatic) and max 5 lesion(s), followed by L19-IL2. The primary objective is PFS at 1.5 years | |
| **LAT FLOSI**<br>Local AblativeTherapy for oligoprogressive Non-Small-Cell lung cancer treated with First-line OSImertinib | Observational | EGFR mutated advanced NSCLC | Radiotherapy/Surgery | To observe whether the (repeated) use of local ablative therapy (LAT) with SABR or surgery to ≤ 3 oligoprogressive lesions and continuation of first-line osimertinib improves the progression-free survival (PFS) in patients with EGFR mutated advanced NSCLC and osimertinib as standard first-line treatment | PI:<br>Dr. P. Berkovic, UZ Leuven<br>Local PI:<br>Charlotte Billiet, Iridium Netwerk<br>Contact: charlotte.billiet@gza.be |
| **iTeos-006-trial**<br>A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors | I | First line metastatic NSCLC | Chemotherapy + IO-combination | To characterize the safety and tolerability of<br>EOS884448 (EOS-448) in combination with<br>standard of care and/or investigational therapies and of dostarlimab combined with<br>inupadenant HCl in participants with advanced solid tumors.<br>To determine the recommended phase 2 dose<br>(RP2D) of EOS-448 in combination with | Local PI:<br>Tom Van den Mooter, GZA<br>Contact: tom.vandenmooter@gza.b |

## Actieve studies

| | | | | | |
|---|---|---|---|---|---|
| | | | | standard of care and/or investigational therapies and of inupadenant in combination<br>with dostarlimab in participants with advanced solid tumors. | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |